Cue Biopharma Inc
CUE0.672USD
-0.058-7.94%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
51.38MMarket Cap
LossP/E TTM
More Details of Cue Biopharma Inc Company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Company Info
Ticker SymbolCUE
Company nameCue Biopharma Inc
IPO dateJan 02, 2018
CEOMr. Daniel R. (Dan) Passeri, J.D.
Number of employees41
Security typeOrdinary Share
Fiscal year-endJan 02
Address40 Guest Street
CityBOSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02135
Phone16179492680
Websitehttps://www.cuebiopharma.com/
Ticker SymbolCUE
IPO dateJan 02, 2018
CEOMr. Daniel R. (Dan) Passeri, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel R. (Dan) Passeri, J.D.
Mr. Daniel R. (Dan) Passeri, J.D.
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
164.58K
--
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Dr. Daniel G. (Dan) Baker, M.D.
Dr. Daniel G. (Dan) Baker, M.D.
Interim Chief Development Officer
Interim Chief Development Officer
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
Ms. Lucinda Warren
Ms. Lucinda Warren
Chief Business officer
Chief Business officer
--
--
Mr. Colin G. Sandercock, J.D.
Mr. Colin G. Sandercock, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Dr. Peter A. Kiener, Ph.D.
Dr. Peter A. Kiener, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matteo Levisetti, M.D.
Mr. Matteo Levisetti, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel R. (Dan) Passeri, J.D.
Mr. Daniel R. (Dan) Passeri, J.D.
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
164.58K
--
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Dr. Daniel G. (Dan) Baker, M.D.
Dr. Daniel G. (Dan) Baker, M.D.
Interim Chief Development Officer
Interim Chief Development Officer
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.87%
Catalytic Wealth RIA, LLC
4.34%
The Vanguard Group, Inc.
4.15%
Geode Capital Management, L.L.C.
0.90%
Robertson Stephens Wealth Management, LLC
0.62%
Other
81.12%
Shareholders
Shareholders
Proportion
Bleichroeder LP
8.87%
Catalytic Wealth RIA, LLC
4.34%
The Vanguard Group, Inc.
4.15%
Geode Capital Management, L.L.C.
0.90%
Robertson Stephens Wealth Management, LLC
0.62%
Other
81.12%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.94%
Investment Advisor/Hedge Fund
1.91%
Research Firm
0.52%
Individual Investor
0.35%
Hedge Fund
0.17%
Pension Fund
0.04%
Venture Capital
0.03%
Other
77.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
179
14.76M
19.58%
-2.35M
2025Q1
184
11.80M
15.77%
-6.74M
2024Q4
187
12.14M
19.16%
-6.53M
2024Q3
186
14.27M
23.69%
-3.80M
2024Q2
196
14.21M
29.21%
-5.75M
2024Q1
221
17.52M
36.59%
-3.12M
2023Q4
227
16.02M
35.92%
-2.73M
2023Q3
232
16.26M
36.70%
-4.68M
2023Q2
232
16.06M
37.54%
-1.73M
2023Q1
238
14.06M
33.55%
-4.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bleichroeder LP
5.00M
6.63%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.32M
3.07%
+259.69K
+12.63%
Mar 31, 2025
Geode Capital Management, L.L.C.
693.89K
0.92%
+62.61K
+9.92%
Mar 31, 2025
Robertson Stephens Wealth Management, LLC
478.50K
0.64%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
559.80K
0.74%
-4.98K
-0.88%
Mar 31, 2025
BofA Global Research (US)
324.35K
0.43%
+36.00
+0.01%
Mar 31, 2025
UBS Financial Services, Inc.
61.31K
0.08%
+3.00K
+5.14%
Mar 31, 2025
Advisory Research, Inc.
257.23K
0.34%
--
--
Mar 31, 2025
1919 Investment Counsel, LLC
196.56K
0.26%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
